Drugs / XNW3009
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05324423 | Oct 2021 → Aug 2022 | gout | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04040907 Comparator | Nov 2019 → Jan 2021 | gout | Evopoint Biosciences Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XNW3009 | “XNW3009 0.5 mg Oral Tablet” NCT05324423 ↗ |
| Action | Inhibit | “XNW3009 is a small molecule hURAT1 inhibitor” NCT04040907 ↗ |
| Modality | Small molecule | “XNW3009 is a small molecule hURAT1 inhibitor” NCT04040907 ↗ |
| Route | Oral | “single and multiple oral doses” NCT04040907 ↗ |